Aim To analyse the prognosis of non-valvular atrial fibrillation patients after PCI with hyperhomocysteinemia and CHA2DS2-VASc in Beijing. Methods A total of 1 688 NVAF-PCI patients with CHA2DS2-VASc=0 or 1 was selected to evaluate the risk and influencing factors of major adverse cardiac events (MACE) within 1 year. Patients were divided into two groups according to their plasma homocysteine(Hcy)levels before catheterization:the normal group (1 135 patients, Hcy<15 μmol/L) and the HHcy group (553 patients, Hcy≥15 μmol/L). The primary endpoint was the occurrence of MACE. Results After 1 year of follow-up, HHcy patients had a higher rate of MACE(P=0.017). The main differences between the two groups were ischemic stroke (P=0.009), cardiac death (P=0.046) and non-fatal myocardial infarction (MI)(P=0.044). Conclusion Elevated Hcy levels were independently associated with an increased risk of MACE in non-valvular AF patients with low CHA2DS2-VASc scores after coronary artery stent implantation, and to receive anticoagulant may be effective.